{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:41:49Z","timestamp":1790563309639,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81960548"],"award-info":[{"award-number":["81960548"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guizhou Provincial Natural Science Foundation, China","award":["ZK (2022) key040"],"award-info":[{"award-number":["ZK (2022) key040"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammation"],"DOI":"10.1007\/s10753-024-02056-9","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T18:02:16Z","timestamp":1716314536000},"page":"181-198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["PD-1 Inhibitor Aggravate Irradiation-Induced Myocardial Fibrosis by Regulating TGF-\u03b21\/Smads Signaling Pathway via GSDMD-Mediated Pyroptosis"],"prefix":"10.1007","volume":"48","author":[{"given":"Bibo","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinxiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"OuYang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfa","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"2056_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D.S., and I. Mellman. 2017. Elements of cancer immunity and the cancer-immune set point. Nature 541: 321\u2013330. https:\/\/doi.org\/10.1038\/nature21349.","journal-title":"Nature"},{"key":"2056_CR2","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M., D. Rodriguez-Abreu, A.G. Robinson, et al. 2016. Pembrolizumab versus chemotherapy for pd-l1-positive non-small-cell lung cancer. New England Journal of Medicine 375: 1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"New England Journal of Medicine"},{"key":"2056_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R.J., B. Escudier, D.F. McDermott, et al. 2015. Nivolumab versus everolimus in advanced renal-cell carcinoma. New England Journal of Medicine 373: 1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665.","journal-title":"New England Journal of Medicine"},{"key":"2056_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-018-0693-2","volume":"12","author":"B Tang","year":"2019","unstructured":"Tang, B., X. Yan, X. Sheng, et al. 2019. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. Journal of Hematology & Oncology 12: 7. https:\/\/doi.org\/10.1186\/s13045-018-0693-2.","journal-title":"Journal of Hematology & Oncology"},{"key":"2056_CR5","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1038\/s41467-018-05032-8","volume":"9","author":"SN Gettinger","year":"2018","unstructured":"Gettinger, S.N., J. Choi, N. Mani, et al. 2018. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nature Communications 9: 3196. https:\/\/doi.org\/10.1038\/s41467-018-05032-8.","journal-title":"Nature Communications"},{"key":"2056_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y.Y., K. Shitara, M. Moehler, et al. 2021. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 398: 27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"key":"2056_CR7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/cncr.34565","volume":"129","author":"T Salous","year":"2023","unstructured":"Salous, T., N.A. Shukla, S.K. Althouse, et al. 2023. A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029. Cancer 129: 264\u2013271. https:\/\/doi.org\/10.1002\/cncr.34565.","journal-title":"Cancer"},{"key":"2056_CR8","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng, Y., L. Han, L. Wu, et al. 2022. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: The ASTRUM-005 Randomized Clinical Trial. JAMA 328: 1223\u20131232. https:\/\/doi.org\/10.1001\/jama.2022.16464.","journal-title":"JAMA"},{"key":"2056_CR9","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde, P.M., J. Spicer, S. Lu, et al. 2022. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. New England Journal of Medicine 386: 1973\u20131985. https:\/\/doi.org\/10.1056\/NEJMoa2202170.","journal-title":"New England Journal of Medicine"},{"key":"2056_CR10","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck, M., D. Rodriguez-Abreu, A.G. Robinson, et al. 2021. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >\/= 50. Journal of Clinical Oncology 39: 2339\u20132349. https:\/\/doi.org\/10.1200\/JCO.21.00174.","journal-title":"Journal of Clinical Oncology"},{"key":"2056_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100394","volume":"7","author":"KJ O'Byrne","year":"2022","unstructured":"O\u2019Byrne, K.J., K.H. Lee, S.W. Kim, et al. 2022. First-line nivolumab + ipilimumab in advanced NSCLC: checkMate 227 subpopulation analyses in Asian patients. ESMO Open 7: 100394. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100394.","journal-title":"ESMO Open"},{"key":"2056_CR12","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.jtho.2020.08.022","volume":"15","author":"JW Welsh","year":"2020","unstructured":"Welsh, J.W., J.V. Heymach, C. Guo, et al. 2020. Phase 1\/2 trial of pembrolizumab and concurrent chemoradiation therapy for limited-stage SCLC. Journal of Thoracic Oncology 15: 1919\u20131927. https:\/\/doi.org\/10.1016\/j.jtho.2020.08.022.","journal-title":"Journal of Thoracic Oncology"},{"key":"2056_CR13","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","volume":"22","author":"NK Altorki","year":"2021","unstructured":"Altorki, N.K., T.E. McGraw, A.C. Borczuk, et al. 2021. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: A single-centre, randomised phase 2 trial. The lancet Oncology 22: 824\u2013835. https:\/\/doi.org\/10.1016\/S1470-2045(21)00149-2.","journal-title":"The lancet Oncology"},{"key":"2056_CR14","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel, D.R., C. Faivre-Finn, J.E. Gray, et al. 2022. Five-year survival outcomes from the pacific trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. Journal of Clinical Oncology 40: 1301\u20131311. https:\/\/doi.org\/10.1200\/JCO.21.01308.","journal-title":"Journal of Clinical Oncology"},{"key":"2056_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi, M., X. Zheng, M. Niu, et al. 2022. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Molecular Cancer 21: 28. https:\/\/doi.org\/10.1186\/s12943-021-01489-2.","journal-title":"Molecular Cancer"},{"key":"2056_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jnci.2015.07.005","volume":"27","author":"R Madan","year":"2015","unstructured":"Madan, R., R. Benson, D.N. Sharma, P.K. Julka, and G.K. Rath. 2015. Radiation induced heart disease: Pathogenesis, management and review literature. Journal of the Egyptian National Cancer Institute 27: 187\u2013193. https:\/\/doi.org\/10.1016\/j.jnci.2015.07.005.","journal-title":"Journal of the Egyptian National Cancer Institute"},{"key":"2056_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-020-2071-9","volume":"579","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z., Y. Zhang, S. Xia, et al. 2020. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature 579: 415\u2013420. https:\/\/doi.org\/10.1038\/s41586-020-2071-9.","journal-title":"Nature"},{"key":"2056_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz7548","author":"ZH Zhou","year":"2020","unstructured":"Zhou, Z.H., K. Wang. He, et al. 2020. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science. https:\/\/doi.org\/10.1126\/science.aaz7548.","journal-title":"Science"},{"key":"2056_CR19","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.7150\/ijbs.35460","volume":"15","author":"H Wang","year":"2019","unstructured":"Wang, H., J. Wei, Q. Zheng, et al. 2019. Radiation-induced heart disease: a review of classification, mechanism and prevention. International Journal of Biological Sciences 15: 2128\u20132138. https:\/\/doi.org\/10.7150\/ijbs.35460.","journal-title":"International Journal of Biological Sciences"},{"key":"2056_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1161\/CIRCULATIONAHA.121.056730","volume":"146","author":"H Zhu","year":"2022","unstructured":"Zhu, H., F.X. Galdos, D. Lee, et al. 2022. Identification of pathogenic immune cell subsets associated with checkpoint inhibitor-induced myocarditis. Circulation 146: 316\u2013335. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056730.","journal-title":"Circulation"},{"key":"2056_CR21","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41573-021-00154-z","volume":"20","author":"X Liu","year":"2021","unstructured":"Liu, X., S. Xia, Z. Zhang, H. Wu, and J. Lieberman. 2021. channelling inflammation: gasdermins in physiology and disease. Nature Reviews Drug Discovery 20: 384\u2013405. https:\/\/doi.org\/10.1038\/s41573-021-00154-z.","journal-title":"Nature Reviews. Drug Discovery"},{"key":"2056_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12563","volume":"52","author":"Z Zhaolin","year":"2019","unstructured":"Zhaolin, Z., L. Guohua, W. Shiyuan, and W. Zuo. 2019. Role of pyroptosis in cardiovascular disease. Cell Proliferation 52: e12563. https:\/\/doi.org\/10.1111\/cpr.12563.","journal-title":"Cell Proliferation"},{"key":"2056_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111553","volume":"41","author":"Y Jiang","year":"2022","unstructured":"Jiang, Y., Y. Yang, Y. Hu, et al. 2022. Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade. Cell Reports 41: 111553. https:\/\/doi.org\/10.1016\/j.celrep.2022.111553.","journal-title":"Cell Reports"},{"key":"2056_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nature18629","volume":"535","author":"X Liu","year":"2016","unstructured":"Liu, X., Z. Zhang, J. Ruan, et al. 2016. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 535: 153\u2013158. https:\/\/doi.org\/10.1038\/nature18629.","journal-title":"Nature"},{"key":"2056_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20020360","author":"XCY Pan","year":"2019","unstructured":"Pan, X.C.Y., Y.Y. Cen. Liu, et al. 2019. Dual role of triptolide in interrupting the nlrp3 inflammasome pathway to attenuate cardiac fibrosis. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms20020360.","journal-title":"International Journal of Molecular Sciences"},{"key":"2056_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2174\/1874312901206010080","volume":"6","author":"CM Artlett","year":"2012","unstructured":"Artlett, C.M. 2012. The Role of the NLRP3 Inflammasome in Fibrosis. Open Rheumatology Journal 6: 80\u201386. https:\/\/doi.org\/10.2174\/1874312901206010080.","journal-title":"Open Rheumatology Journal"},{"key":"2056_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng, D., M. Fu, M. Wang, Y. Wei, and X. Wei. 2022. Targeting TGF-beta signal transduction for fibrosis and cancer therapy. Molecular Cancer 21: 104. https:\/\/doi.org\/10.1186\/s12943-022-01569-x.","journal-title":"Molecular Cancer"},{"key":"2056_CR28","doi-asserted-by":"publisher","first-page":"7717","DOI":"10.1111\/jcmm.15479","volume":"24","author":"B Wang","year":"2020","unstructured":"Wang, B., H. Wang, M. Zhang, et al. 2020. Radiation-induced myocardial fibrosis: Mechanisms underlying its pathogenesis and therapeutic strategies. Journal of Cellular and Molecular Medicine 24: 7717\u20137729. https:\/\/doi.org\/10.1111\/jcmm.15479.","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"2056_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.110289","volume":"369","author":"LL Ren","year":"2023","unstructured":"Ren, L.L., X.J. Li, T.T. Duan, et al. 2023. Transforming growth factor-beta signaling: from tissue fibrosis to therapeutic opportunities. Chemico-Biological Interactions 369: 110289. https:\/\/doi.org\/10.1016\/j.cbi.2022.110289.","journal-title":"Chemico-Biological Interactions"},{"key":"2056_CR30","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.1096\/fj.201902692R","volume":"34","author":"H Che","year":"2020","unstructured":"Che, H., Y. Wang, H. Li, et al. 2020. Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1\/miR-141-mediated NLRP3 inflammasome and TGF-beta1\/Smads signaling in diabetic cardiomyopathy. The FASEB Journal 34: 5282\u20135298. https:\/\/doi.org\/10.1096\/fj.201902692R.","journal-title":"The FASEB Journal"},{"key":"2056_CR31","doi-asserted-by":"publisher","first-page":"2466150","DOI":"10.1155\/2022\/2466150","volume":"2022","author":"C Ge","year":"2022","unstructured":"Ge, C., Y. Zhao, Y. Liang, and Y. He. 2022. Silencing of TLR4 inhibits atrial fibrosis and susceptibility to atrial fibrillation via downregulation of NLRP3-TGF-beta in spontaneously hypertensive rats. Disease Markers 2022: 2466150. https:\/\/doi.org\/10.1155\/2022\/2466150.","journal-title":"Disease Markers"},{"key":"2056_CR32","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2147\/JIR.S348464","volume":"15","author":"H Zhang","year":"2022","unstructured":"Zhang, H., J. Lin, Y. Shen, et al. 2022. Protective effect of crocin on immune checkpoint inhibitors-related myocarditis through inhibiting NLRP3 mediated pyroptosis in cardiomyocytes via NF-kappaB pathway. Journal of Inflammation Research 15: 1653\u20131666. https:\/\/doi.org\/10.2147\/JIR.S348464.","journal-title":"Journal of Inflammation Research"},{"key":"2056_CR33","doi-asserted-by":"publisher","first-page":"8007078","DOI":"10.1155\/2022\/8007078","volume":"2022","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y., Z. Yao, Y. Xiao, X. Zhang, and J. Liu. 2022. Downregulated XBP-1 rescues cerebral ischemia\/reperfusion injury-induced pyroptosis via the NLRP3\/caspase-1\/GSDMD Axis. Mediators of Inflammation 2022: 8007078. https:\/\/doi.org\/10.1155\/2022\/8007078.","journal-title":"Mediators of Inflammation"},{"key":"2056_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03157-7","author":"J Shen","year":"2020","unstructured":"Shen, J., J.M. Wu, G.M. Hu, et al. 2020. Membrane nanotubes facilitate the propagation of inflammatory injury in the heart upon overactivation of the beta-adrenergic receptor. Cell Death and Disease. https:\/\/doi.org\/10.1038\/s41419-020-03157-7.","journal-title":"Cell Death and Disease"},{"key":"2056_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2021.112351","volume":"219","author":"J Li","year":"2021","unstructured":"Li, J., Z. An, J. Song, et al. 2021. Fine particulate matter-induced lung in flammation is mediated by pyroptosis in mice. Ecotoxicology and Environmental Safety 219: 112351. https:\/\/doi.org\/10.1016\/j.ecoenv.2021.112351.","journal-title":"Ecotoxicology and Environmental Safety"},{"key":"2056_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/exd.13436","volume":"27","author":"R Chakraborty","year":"2018","unstructured":"Chakraborty, R., J. Chandra, S. Cui, et al. 2018. CD8(+) lineage dendritic cells determine adaptive immune responses to inflammasome activation upon sterile skin injury. Experimental Dermatology 27: 71\u201379. https:\/\/doi.org\/10.1111\/exd.13436.","journal-title":"Experimental Dermatology"},{"key":"2056_CR37","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s10753-021-01429-8","volume":"44","author":"BJ Laird","year":"2021","unstructured":"Laird, B.J., D. McMillan, R.J.E. Skipworth, et al. 2021. The emerging role of interleukin 1beta (IL-1beta) in cancer cachexia. Inflammation 44: 1223\u20131228. https:\/\/doi.org\/10.1007\/s10753-021-01429-8.","journal-title":"Inflammation"},{"key":"2056_CR38","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cytogfr.2011.10.001","volume":"22","author":"G Lopez-Castejon","year":"2011","unstructured":"Lopez-Castejon, G., and D. Brough. 2011. Understanding the mechanism of IL-1beta secretion. Cytokine & Growth Factor Reviews 22: 189\u2013195. https:\/\/doi.org\/10.1016\/j.cytogfr.2011.10.001.","journal-title":"Cytokine & Growth Factor Reviews"},{"key":"2056_CR39","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1073\/pnas.1812266115","volume":"116","author":"I Kaplanov","year":"2019","unstructured":"Kaplanov, I., Y. Carmi, R. Kornetsky, et al. 2019. Blocking IL-1beta reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proceedings\u00a0of the\u00a0National Academy\u00a0of\u00a0Sciences USA 116: 1361\u20131369. https:\/\/doi.org\/10.1073\/pnas.1812266115.","journal-title":"Proceedings\u00a0of the\u00a0National Academy\u00a0of\u00a0Sciences USA"},{"key":"2056_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cyto.2018.01.008","volume":"118","author":"PM Nguyen","year":"2019","unstructured":"Nguyen, P.M., and T.L. Putoczki. 2019. Could the inhibition of IL-17 or IL-18 be a potential therapeutic opportunity for gastric cancer? Cytokine 118: 8\u201318. https:\/\/doi.org\/10.1016\/j.cyto.2018.01.008.","journal-title":"Cytokine"},{"key":"2056_CR41","doi-asserted-by":"publisher","unstructured":"Celada, L.J.,\u00a0J.A.  Kropski, J.D. Herazo-Maya. et al. 2018. PD-1 up-regulation on CD4(+) T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-beta1 production.\u00a0Science Translational Medicine\u00a010.\u00a0https:\/\/doi.org\/10.1126\/scitranslmed.aar8356.","DOI":"10.1126\/scitranslmed.aar8356"},{"key":"2056_CR42","doi-asserted-by":"publisher","unstructured":"Iwakura, Y.,  H. Ishigame,  S. Saijo,  S. Nakae. 2011. Functional specialization of interleukin-17 family members. Immunity 34: 149\u2013162.\u00a0https:\/\/doi.org\/10.1016\/j.immuni.2011.02.012.","DOI":"10.1016\/j.immuni.2011.02.012"},{"key":"2056_CR43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.gene.2017.01.016","volume":"614","author":"K Chen","year":"2017","unstructured":"Chen, K., and J.K. Kolls. 2017. Interluekin-17A (IL17A). Gene 614: 8\u201314. https:\/\/doi.org\/10.1016\/j.gene.2017.01.016.","journal-title":"Gene"},{"key":"2056_CR44","doi-asserted-by":"publisher","unstructured":"de Streel, G., and S. Lucas. 2021. Targeting immunosuppression by TGF-beta1 for cancer immunotherapy.\u00a0Biochemical Pharmacology\u00a0192: 114697.https:\/\/doi.org\/10.1016\/j.bcp.2021.114697.","DOI":"10.1016\/j.bcp.2021.114697"},{"key":"2056_CR45","doi-asserted-by":"publisher","unstructured":"Batlle, E., and J. Massague. 2019. Transforming growth factor-beta signaling in immunity and cancer. Immunity 50: 924\u2013940.\u00a0https:\/\/doi.org\/10.1016\/j.immuni.2019.03.024.","DOI":"10.1016\/j.immuni.2019.03.024"},{"key":"2056_CR46","doi-asserted-by":"publisher","unstructured":"Apte, R.S., D.S. Chen, N. Ferrara. 2019. VEGF in signaling and disease: beyond discovery and development. Cell 176: 1248\u20131264.\u00a0https:\/\/doi.org\/10.1016\/j.cell.2019.01.021.","DOI":"10.1016\/j.cell.2019.01.021"},{"key":"2056_CR47","doi-asserted-by":"publisher","unstructured":"Iyer, A.K. Ramesh, V. Castro, C.A., et al. 2015. Nitric oxide mediates bleomycin-induced angiogenesis and pulmonary fibrosis via regulation of VEGF.\u00a0Journal\u00a0of\u00a0Cellular Biochemistry\u00a0116: 2484\u20132493.\u00a0https:\/\/doi.org\/10.1002\/jcb.25192.","DOI":"10.1002\/jcb.25192"},{"key":"2056_CR48","doi-asserted-by":"publisher","unstructured":"Zou, C.,  W. Li, Y. Pan. et al. 2017. 11beta-HSD1 inhibition ameliorates diabetes-induced cardiomyocyte hypertrophy and cardiac fibrosis through modulation of EGFR activity. Oncotarget 8: 96263\u201396275. https:\/\/doi.org\/10.18632\/oncotarget.22015.","DOI":"10.18632\/oncotarget.22015"},{"key":"2056_CR49","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/09031936.00152106","volume":"29","author":"NI Chaudhary","year":"2007","unstructured":"Chaudhary, N.I., G.J. Roth, F. Hilberg, et al. 2007. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. European Respiratory Journal 29: 976\u2013985. https:\/\/doi.org\/10.1183\/09031936.00152106.","journal-title":"European Respiratory Journal"},{"key":"2056_CR50","doi-asserted-by":"publisher","unstructured":"Venkatadri, R., A.K. Iyer, V. Ramesh. et al. 2017. MnTBAP Inhibits bleomycin-induced pulmonary fibrosis by regulating VEGF and wnt signaling.\u00a0Journal\u00a0of\u00a0Cellular Physiology\u00a0232: 506\u2013516.\u00a0https:\/\/doi.org\/10.1002\/jcp.25608.","DOI":"10.1002\/jcp.25608"},{"issue":"3","key":"2056_CR51","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000088478","volume":"69","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet, P. 2005. VEGF as a key mediator of angiogenesis in cancer. Oncology 69 (3): 4\u201310. https:\/\/doi.org\/10.1159\/000088478.","journal-title":"Oncology"},{"key":"2056_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19041232","author":"Y Itatani","year":"2018","unstructured":"Itatani, Y., K. Kawada, T. Yamamoto, and Y. Sakai. 2018. Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms19041232.","journal-title":"International Journal of Molecular Sciences"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-024-02056-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10753-024-02056-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-024-02056-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T11:18:39Z","timestamp":1739359119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10753-024-02056-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["2056"],"URL":"https:\/\/doi.org\/10.1007\/s10753-024-02056-9","relation":{},"ISSN":["1573-2576"],"issn-type":[{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"2 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"There are some limitations to this study. First of all, in most animal models established by researchers to explore the mechanism of RIHD, the irradiation method is to receive the same dose of whole-heart irradiation, which does not involve in vivo tumors. However, in clinical practice, the radiation dose received by different areas in the heart of patients with thoracic tumors varies greatly. A single dose of 20\u00a0Gy to the heart is not directly related to exposure to radiation therapy. Secondly, only male mice were studied, and the effects on female mice may be different. Thirdly, each of the analyses contained a very small number of mice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Limitations"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}